Screening for Prostate Cancer in 2008 II: The Importance of Molecular Subforms of Prostate-Specific Antigen and Tissue Kallikreins

European Urology

Volumn 55, Issue 3, 2009, Pages 563-574

  Jansen, Flip H ^a   Roobol, Monique ^a   Jenster, Guido ^a   Schröder, Fritz H ^a   Bangma, Chris H ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

BPSA; Prostate cancer screening; PSA isoforms; Tissue kallikreins

Indexed keywords

BIOLOGICAL MARKER; KALLIKREIN 11; KALLIKREIN 13; KALLIKREIN 2; KALLIKREIN 5; KALLIKREIN 6; PROSTATE SPECIFIC ANTIGEN; TISSUE KALLIKREIN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; CANCER DIAGNOSIS; CANCER GRADING; CANCER RECURRENCE; CANCER RESEARCH; CANCER SCREENING; DOWN REGULATION; HISTOPATHOLOGY; HUMAN; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; REVIEW; SENSITIVITY AND SPECIFICITY; TUMOR BIOPSY;

BIOLOGICAL MARKERS; HUMANS; MALE; MASS SCREENING; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; PROTEIN ISOFORMS; PROTEIN PRECURSORS; TISSUE KALLIKREINS;

EID: 58849141177     PISSN: 03022838     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.eururo.2008.11.040     Document Type: Review

References (84)

1. Lilja H. A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein. J Clin Invest 76 (1985) 1899-1903
2. Magklara A., Scorilas A., Stephan C., et al. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology 56 (2000) 527-532
3. Balk S.P., Ko Y.J., and Bubley G.J. Biology of prostate-specific antigen. J Clin Oncol 21 (2003) 383-391
4. Mikolajczyk S.D., Marks L.S., Partin A.W., and Rittenhouse H.G. Free prostate-specific antigen in serum is becoming more complex. Urology 59 (2002) 797-802
5. Yousef G.M., Luo L.Y., and Diamandis E.P. Identification of novel human kallikrein-like genes on chromosome 19q13.3-q13.4. Anticancer Res 19 (1999) 2843-2852
6. Lundwall A., Band V., Blaber M., et al. A comprehensive nomenclature for serine proteases with homology to tissue kallikreins. Biol Chem 387 (2006) 637-641
7. Nelson P.S., Gan L., Ferguson C., et al. Molecular cloning and characterization of prostase, an androgen-regulated serine protease with prostate-restricted expression. Proc Natl Acad Sci U S A 96 (1999) 3114-3119
8. Young C.Y., Andrews P.E., Montgomery B.T., and Tindall D.J. Tissue-specific and hormonal regulation of human prostate-specific glandular kallikrein. Biochemistry 31 (1992) 818-824
9. Lundwall A., and Lilja H. Molecular cloning of human prostate specific antigen cDNA. FEBS Lett 214 (1987) 317-322
10. Darson M.F., Pacelli A., Roche P., et al. Human glandular kallikrein 2 (hK2) expression in prostatic intraepithelial neoplasia and adenocarcinoma: a novel prostate cancer marker. Urology 49 (1997) 857-862
11. Kumar A., Mikolajczyk S.D., Goel A.S., Millar L.S., and Saedi M.S. Expression of pro form of prostate-specific antigen by mammalian cells and its conversion to mature, active form by human kallikrein 2. Cancer Res 57 (1997) 3111-3114
12. Mikolajczyk S.D., Marker K.M., Millar L.S., et al. A truncated precursor form of prostate-specific antigen is a more specific serum marker of prostate cancer. Cancer Res 61 (2001) 6958-6963
13. Peter J., Unverzagt C., Krogh T.N., Vorm O., and Hoesel W. Identification of precursor forms of free prostate-specific antigen in serum of prostate cancer patients by immunosorption and mass spectrometry. Cancer Res 61 (2001) 957-962
14. Noldus J., Chen Z., and Stamey T.A. Isolation and characterization of free form prostate specific antigen (f-PSA) in sera of men with prostate cancer. J Urol 158 (1997) 1606-1609
15. Lovgren J., Rajakoski K., Karp M., Lundwall A., and Lilja H. Activation of the zymogen form of prostate-specific antigen by human glandular kallikrein 2. Biochem Biophys Res Commun 238 (1997) 549-555
16. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. A precursor form of prostate-specific antigen is more highly elevated in prostate cancer compared with benign transition zone prostate tissue. Cancer Res 60 (2000) 756-759
17. Hilz H., Noldus J., Hammerer P., et al. Molecular heterogeneity of free PSA in sera of patients with benign and malignant prostate tumors. Eur Urol 36 (1999) 286-292
18. Naya Y., Fritsche H.A., Bhadkamkar V.A., et al. Volume-based evaluation of serum assays for new prostate-specific antigen isoforms in the detection of prostate cancer. Urology 63 (2004) 492-498
19. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro prostate specific antigen improves cancer detection compared to free and complexed prostate specific antigen in men with prostate specific antigen 2 to 4 ng/ml. J Urol 170 (2003) 2181-2185
20. Catalona W.J., Bartsch G., Rittenhouse H.G., et al. Serum pro-prostate specific antigen preferentially detects aggressive prostate cancers in men with 2 to 4 ng/ml prostate specific antigen. J Urol 171 (2004) 2239-2244
21. Naya Y., Fritsche H.A., Bhadkamkar V.A., et al. Evaluation of precursor prostate-specific antigen isoform ratios in the detection of prostate cancer. Urol Oncol 23 (2005) 16-21
22. Mikolajczyk S.D., Catalona W.J., Evans C.L., et al. Proenzyme forms of prostate-specific antigen in serum improve the detection of prostate cancer. Clin Chem 50 (2004) 1017-1025
23. de Vries S.H., Raaijmakers R., Blijenberg B.G., et al. Additional use of [-2] precursor prostate-specific antigen and "benign" PSA at diagnosis in screen-detected prostate cancer. Urology 65 (2005) 926-930
24. Bangma C.H., Wildhagen M.F., Yurdakul G., Schroder F.H., and Blijenberg B.G. The value of (-7, -5) pro-prostate-specific antigen and human kallikrein-2 as serum markers for grading prostate cancer. BJU Int 93 (2004) 720-724
25. Stephan C., Meyer H.-A., Kwiatkowski M., et al. A (-5, -7) proPSA based artificial neural network to detect prostate cancer. Eur Urol 50 (2006) 1014-1020
26. Lein M., Semjonow A., Graefen M., et al. A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. J Urol 174 (2005) 2150-2153
27. Mikolajczyk S.D., Millar L.S., Wang T.J., et al. "BPSA", a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. Urology 55 (2000) 41-45
28. Linton H.J., Marks L.S., Millar L.S., et al. Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. Clin Chem 49 (2003) 253-259
29. Canto E.I., Singh H., Shariat S.F., et al. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. Urology 63 (2004) 905-911 discussion 910-1
30. Becker C., Piironen T., Kiviniemi J., Lilja H., and Pettersson K. Sensitive and specific immunodetection of human glandular kallikrein 2 in serum. Clin Chem 46 (2000) 198-206
31. Finlay J.A., Evans C.L., Day J.R., et al. Development of monoclonal antibodies specific for human glandular kallikrein (hK2): development of a dual antibody immunoassay for hK2 with negligible prostate-specific antigen cross-reactivity. Urology 51 (1998) 804-809
32. Charlesworth M.C., Young C.Y., Klee G.G., et al. Detection of a prostate-specific protein, human glandular kallikrein (hK2), in sera of patients with elevated prostate-specific antigen levels. Urology 49 (1997) 487-493
33. Tremblay R.R., Deperthes D., Tetu B., and Dube J.Y. Immunohistochemical study suggesting a complementary role of kallikreins hK2 and hK3 (prostate-specific antigen) in the functional analysis of human prostate tumors. Am J Pathol 150 (1997) 455-459
34. Kwiatkowski M.K., Recker F., Piironen T., et al. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL. Urology 52 (1998) 360-365
35. Magklara A., Scorilas A., Catalona W.J., and Diamandis E.P. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem 45 (1999) 1960-1966
36. Partin A.W., Catalona W.J., Finlay J.A., et al. Use of human glandular kallikrein 2 for the detection of prostate cancer: preliminary analysis. Urology 54 (1999) 839-845
37. Stephan C., Jung K., Soosaipillai A., et al. Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection. BJU Int 96 (2005) 521-527
38. Becker C., Piironen T., Pettersson K., et al. Discrimination of men with prostate cancer from those with benign disease by measurements of human glandular kallikrein 2 (HK2) in serum. J Urol 163 (2000) 311-316
39. Becker C., Piironen T., Pettersson K., Hugosson J., and Lilja H. Clinical value of human glandular kallikrein 2 and free and total prostate-specific antigen in serum from a population of men with prostate-specific antigen levels 3.0 ng/mL or greater. Urology 55 (2000) 694-699
40. Nam R.K., Diamandis E.P., Toi A., et al. Serum human glandular kallikrein-2 protease levels predict the presence of prostate cancer among men with elevated prostate-specific antigen. J Clin Oncol 18 (2000) 1036-1042
41. Recker F., Kwiatkowski M.K., Piironen T., et al. The importance of human glandular kallikrein and its correlation with different prostate specific antigen serum forms in the detection of prostate carcinoma. Cancer 83 (1998) 2540-2547
42. Scorilas A., Plebani M., Mazza S., et al. Serum human glandular kallikrein (hK2) and insulin-like growth factor 1 (IGF-1) improve the discrimination between prostate cancer and benign prostatic hyperplasia in combination with total and %free PSA. Prostate 54 (2003) 220-229
43. Steuber T., Vickers A., Haese A., et al. Free PSA isoforms and intact and cleaved forms of urokinase plasminogen activator receptor in serum improve selection of patients for prostate cancer biopsy. Int J Cancer 120 (2007) 1499-1504
44. Vickers A.J., Ulmert D., Serio A.M., et al. The predictive value of prostate cancer biomarkers depends on age and time to diagnosis: towards a biologically-based screening strategy. Int J Cancer 121 (2007) 2212-2217
45. Haese A., Becker C., Noldus J., et al. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J Urol 163 (2000) 1491-1497
46. Haese A., Graefen M., Becker C., et al. The role of human glandular kallikrein 2 for prediction of pathologically organ confined prostate cancer. Prostate 54 (2003) 181-186
47. Haese A., Graefen M., Steuber T., et al. Human glandular kallikrein 2 levels in serum for discrimination of pathologically organ-confined from locally-advanced prostate cancer in total PSA-levels below 10 ng/ml. Prostate 49 (2001) 101-109
48. Recker F., Kwiatkowski M.K., Piironen T., et al. Human glandular kallikrein as a tool to improve discrimination of poorly differentiated and non-organ-confined prostate cancer compared with prostate-specific antigen. Urology 55 (2000) 481-485
49. Steuber T., Vickers A.J., Serio A.M., et al. Comparison of free and total forms of serum human kallikrein 2 and prostate-specific antigen for prediction of locally advanced and recurrent prostate cancer. Clin Chem 53 (2007) 233-240
50. Stephan C., Jung K., Nakamura T., et al. Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer. Int J Urol 13 (2006) 238-243
51. Vaisanen V., Pettersson K., Alanen K., Viitanen T., and Nurmi M. Free and total human glandular kallikrein 2 in patients with prostate cancer. Urology 68 (2006) 219-225
52. Diamandis E.P., Okui A., Mitsui S., et al. Human kallikrein 11: a new biomarker of prostate and ovarian carcinoma. Cancer Res 62 (2002) 295-300
53. Yoshida S., Taniguchi M., Suemoto T., et al. cDNA cloning and expression of a novel serine protease, TLSP. Biochim Biophys Acta 1399 (1998) 225-228
54. Yousef G.M., Scorilas A., and Diamandis E.P. Genomic organization, mapping, tissue expression, and hormonal regulation of trypsin-like serine protease (TLSP PRSS20), a new member of the human kallikrein gene family. Genomics 63 (2000) 88-96
55. Nakamura T., Scorilas A., Stephan C., et al. The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. Cancer Res 63 (2003) 6543-6546
56. Stephan C., Xu C., Brown D.A., et al. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network. Prostate 66 (2006) 651-659
57. Stephan C., Meyer H.A., Cammann H., et al. Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network. Biol Chem 387 (2006) 801-805
58. Ochiai A., Shukla A., Davis J.W., et al. Is there a role for serum human tissue kallikrein in detection of prostate cancer?. Urology 70 (2007) 519-522
59. Shaw J.L., and Diamandis E.P. Distribution of 15 human kallikreins in tissues and biological fluids. Clin Chem 53 (2007) 1423-1432
60. Day C.H., Fanger G.R., Retter M.W., et al. Characterization of KLK4 expression and detection of KLK4-specific antibody in prostate cancer patient sera. Oncogene 21 (2002) 7114-7120
61. Xi Z., Klokk T.I., Korkmaz K., et al. Kallikrein 4 is a predominantly nuclear protein and is overexpressed in prostate cancer. Cancer Res 64 (2004) 2365-2370
62. Obiezu C.V., Shan S.J., Soosaipillai A., et al. Human kallikrein 4: quantitative study in tissues and evidence for its secretion into biological fluids. Clin Chem 51 (2005) 1432-1442
63. Obiezu C.V., Soosaipillai A., Jung K., et al. Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. Clin Chem 48 (2002) 1232-1240
64. Kurlender L., Yousef G.M., Memari N., et al. Differential expression of a human kallikrein 5 (KLK5) splice variant in ovarian and prostate cancer. Tumour Biol 25 (2004) 149-156
65. Yousef G.M., Scorilas A., Chang A., et al. Down-regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues. Prostate 51 (2002) 126-132
66. Petraki C.D., Gregorakis A.K., Papanastasiou P.A., et al. Immunohistochemical localization of human kallikreins 6, 10 and 13 in benign and malignant prostatic tissues. Prostate Cancer Prostatic Dis 6 (2003) 223-227
67. Kishi T., Soosaipillai A., Grass L., et al. Development of an immunofluorometric assay and quantification of human kallikrein 7 in tissue extracts and biological fluids. Clin Chem 50 (2004) 709-716
68. Yousef G.M., and Diamandis E.P. The expanded human kallikrein gene family: locus characterization and molecular cloning of a new member, KLK-L3 (KLK9). Genomics 65 (2000) 184-194
69. Goyal J., Smith K.M., Cowan J.M., et al. The role for NES1 serine protease as a novel tumor suppressor. Cancer Res 58 (1998) 4782-4786
70. Kapadia C., Chang A., Sotiropoulou G., et al. Human kallikrein 13: production and purification of recombinant protein and monoclonal and polyclonal antibodies, and development of a sensitive and specific immunofluorometric assay. Clin Chem 49 (2003) 77-86
71. Yousef G.M., Magklara A., and Diamandis E.P. KLK12 is a novel serine protease and a new member of the human kallikrein gene family-differential expression in breast cancer. Genomics 69 (2000) 331-341
72. Emami N., Deperthes D., Malm J., and Diamandis E.P. Major role of human KLK14 in seminal clot liquefaction. J Biol Chem 283 (2008) 19561-19569
73. Borgono C.A., Michael I.P., Shaw J.L., et al. Expression and functional characterization of the cancer-related serine protease, human tissue kallikrein 14. J Biol Chem 282 (2007) 2405-2422
74. Rabien A., Fritzsche F., Jung M., et al. High expression of KLK14 in prostatic adenocarcinoma is associated with elevated risk of prostate-specific antigen relapse. Tumour Biol 29 (2008) 1-8
75. Yousef G.M., Magklara A., Chang A., et al. Cloning of a new member of the human kallikrein gene family, KLK14, which is down-regulated in different malignancies. Cancer Res 61 (2001) 3425-3431
76. Yousef G.M., Stephan C., Scorilas A., et al. Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues. Prostate 56 (2003) 287-292
77. Stephan C., Yousef G.M., Scorilas A., et al. Quantitative analysis of kallikrein 15 gene expression in prostate tissue. J Urol 169 (2003) 361-364
78. Yousef G.M., Scorilas A., Jung K., Ashworth L.K., and Diamandis E.P. Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer. J Biol Chem 276 (2001) 53-61
79. Shaw J.L., Grass L., Sotiropoulou G., and Diamandis E.P. Development of an immunofluorometric assay for human kallikrein 15 (KLK15) and identification of KLK15 in tissues and biological fluids. Clin Biochem 40 (2007) 104-110
80. Andriole G.L., Levin D.L., Crawford E.D., et al. Prostate cancer screening in the Prostate, Lung. Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst 97 (2005) 433-438
81. Catalona W.J., Richie J.P., Ahmann F.R., et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol 151 (1994) 1283-1290
82. Catalona W.J., Smith D.S., Ratliff T.L., et al. Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324 (1991) 1156-1161
83. Thompson I.M., Pauler D.K., Goodman P.J., et al. Prevalence of prostate cancer among men with a prostate-specific antigen level < or =4.0 ng per millilitre. N Engl J Med 350 (2004) 2239-2246
84. Mikolajczyk S.D., and Rittenhouse H.G. Pro PSA: a more cancer specific form of prostate specific antigen for the early detection of prostate cancer. Keio J Med 52 (2003) 86-91